HC Wainwright Has Pessimistic Outlook of MIST Q1 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Research analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for Milestone Pharmaceuticals in a note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.17). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q2 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at ($0.02) EPS.

Milestone Pharmaceuticals Stock Down 2.6 %

Shares of NASDAQ MIST opened at $1.90 on Thursday. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The company has a market cap of $101.37 million, a P/E ratio of -2.35 and a beta of 1.83. Milestone Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $2.75. The business has a 50-day simple moving average of $2.01 and a two-hundred day simple moving average of $1.82.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of large investors have recently modified their holdings of MIST. Atria Investments Inc lifted its stake in Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after purchasing an additional 12,430 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of Milestone Pharmaceuticals in the third quarter worth $46,000. Jones Financial Companies Lllp raised its position in shares of Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after buying an additional 10,000 shares in the last quarter. Virtu Financial LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter valued at $170,000. Finally, National Bank of Canada FI grew its position in Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after buying an additional 11,600 shares in the last quarter. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.